Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?
- 13 February 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 12 (3) , 327-339
Abstract
Endothelin-1 (ET-1) and urotensin II (U-II) are the most potent and unusually long-lasting constrictors of human vessels known to date. In this review, we focus on the vascular effects of endothelin-1 (ET-1) and urotensin II (U-II) and their role in the pathophysiology of hypertension. Unlike ET-1, which uniformly constricts most blood vessels, the vasoactive effects of U-II depend both on the species, vascular bed and vessel calibre. Both ET-1 and U-II have potent mitogenic, pro-inflammatory and pro-oxidative properties, which have been implicated in the pathogenesis of human cardiovascular and renal diseases. The availability of highly effective peptide and non-peptide antagonists both for ET-1 and U-II receptors has revealed a role for these potent vasoconstrictor peptides in human (patho)physiology.Keywords
This publication has 99 references indexed in Scilit:
- Deletion of Endothelial Cell Endothelin B Receptors Does Not Affect Blood Pressure or Sensitivity to SaltHypertension, 2006
- The role of urotensin II in cardiovascular and renal physiology and diseasesBritish Journal of Pharmacology, 2006
- Human Urotensin II Accelerates Foam Cell Formation in Human Monocyte-Derived MacrophagesHypertension, 2005
- Endothelium-Restricted Overexpression of Human Endothelin-1 Causes Vascular Remodeling and Endothelial DysfunctionCirculation, 2004
- Ethnic Differences in the Vasoconstrictor Activity of Endogenous Endothelin-1 in Hypertensive PatientsCirculation, 2004
- Enhanced Vascular Activity of Endogenous Endothelin-1 in Obese Hypertensive PatientsHypertension, 2004
- Endothelin-1 Increases Vascular Superoxide via Endothelin A –NADPH Oxidase Pathway in Low-Renin HypertensionCirculation, 2003
- Flow-Induced Pressure Differentially Regulates Endothelin-1, Urotensin II, Adrenomedullin, and Relaxin in Pulmonary Vascular EndotheliumBiochemical and Biophysical Research Communications, 2001
- Identification of Urotensin II as the Endogenous Ligand for the Orphan G-Protein-Coupled Receptor GPR14Biochemical and Biophysical Research Communications, 1999
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998